Literature DB >> 20175906

Quality assurance for Chinese herbal formulae: standardization of IBS-20, a 20-herb preparation.

Siu-Po Ip1, Ming Zhao, Yanfang Xian, Mengli Chen, Yuying Zong, Yung-Wui Tjong, Sam-Hip Tsai, Joseph J Y Sung, Alan Bensoussan, Brian Berman, Harry H S Fong, Chun-Tao Che.   

Abstract

BACKGROUND: The employment of well characterized test samples prepared from authenticated, high quality medicinal plant materials is key to reproducible herbal research. The present study aims to demonstrate a quality assurance program covering the acquisition, botanical validation, chemical standardization and good manufacturing practices (GMP) production of IBS-20, a 20-herb Chinese herbal formula under study as a potential agent for the treatment of irritable bowel syndrome.
METHODS: Purity and contaminant tests for the presence of toxic metals, pesticide residues, mycotoxins and microorganisms were performed. Qualitative chemical fingerprint analysis and quantitation of marker compounds of the herbs, as well as that of the IBS-20 formula was carried out with high-performance liquid chromatography (HPLC). Extraction and manufacture of the 20-herb formula were carried out under GMP. Chemical standardization was performed with liquid chromatography-mass spectrometry (LC-MS) analysis. Stability of the formula was monitored with HPLC in real time.
RESULTS: Quality component herbs, purchased from a GMP supplier were botanically and chemically authenticated and quantitative HPLC profiles (fingerprints) of each component herb and of the composite formula were established. An aqueous extract of the mixture of the 20 herbs was prepared and formulated into IBS-20, which was chemically standardized by LC-MS, with 20 chemical compounds serving as reference markers. The stability of the formula was monitored and shown to be stable at room temperature.
CONCLUSION: A quality assurance program has been developed for the preparation of a standardized 20-herb formulation for use in the clinical studies for the treatment of irritable bowel syndrome (IBS). The procedures developed in the present study will serve as a protocol for other poly-herbal Chinese medicine studies.

Entities:  

Year:  2010        PMID: 20175906      PMCID: PMC2845568          DOI: 10.1186/1749-8546-5-8

Source DB:  PubMed          Journal:  Chin Med        ISSN: 1749-8546            Impact factor:   5.455


Background

Herbal medicines, whether in the form of single herb phytomedicine or multiple herb mixtures, are popular around the world. However, evidence of efficacy and safety has not been well documented [1]. Lack of effective quality assurance affects the efficacy and safety assessment of herbal products [1-7]. For valid pharmacological or clinical efficacy evaluations, a standardized single batch clinical formulation should be employed. As part of a research project to evaluate the therapeutic potential of a 20-herb Chinese medicine formula (the IBS-20 formula) for treating irritable bowel syndrome (IBS), we have developed and tested a quality assurance program for the production of the multi-herb preparation. IBS affects 10-20% of the global population [8] and it has not been successfully treated with conventional medications such as bulking, smooth muscle relaxant, prokinetic and psychotropic agents, nor loperamide and peppermint oil [9]. We are presently conducting a clinical study of a 20-herb Chinese medicine formula (IBS-20) to determine its efficacy potential in the treatment of this disorder. To insure the validity and reproducible results in conducting this study, we established a robust quality assurance (QA)/quality control (QC) program. The present paper describes the methods employed, covering all aspects of the production of IBS-20 from source material acquisition, botanical validation, chemical standardization, extraction and formulation. The protocols established in this study may be used as a model for the quality assurance of other herbal products.

Methods

Plant materials

The component herbs in the formula are as follows: Pogostemon cablin (herb) (4.5%, w/w), Angelica dahurica (root) (2%), Artemisia scoparia (herb) (13%), Atractylodes macrocephala (rhizome)(9%), Aucklandia lappa (root) (3%), Bupleurum chinense (root) (4.5%), Citrus reticulate (fruit peel) (3%), Codonopsis pilosula (root) (7%), Coix lacryma-jobi (seed) (7%), Coptis chinensis (rhizome) (3%), Fraxinus rhynchophylla (bark) (4.5%), Glycyrrhiza uralensis (root) (4.5%), Magnolia officinalis (bark) (4.5%), Paeonia lactiflora (root)(3%), Plantago asiatica (seed) (4.5%), Phellodendron amurense (bark) (4.5%), Poria cocos (fruiting body) (4.5%), Saposhnikovia divaricata (root) (3%), Schisandra chinensis (fruit) (7%) and Zingiber officinale (rhizome) (4.5%). All 20 herbs were acquired in the prescribed proportions (% w/w) from Zhixin Chinese Pharmaceutical Co. Ltd. (Guangzhou, China). The aggregate weight of the 20 herbs was 400 kg (Additional File 1). Voucher samples (#IBS-01 to IBS-20) were deposited at the herbarium of the School of Chinese Medicine, Chinese University of Hong Kong (Hong Kong SAR, China). The individual bulk herb samples were stored in air-tight containers kept in air-conditioned environment until use. The herbs were identified in both Chinese and botanical (Latin binomial) names. When two or more species share the same Chinese name, only one species was selected for chemical and biological/clinical studies.

Botanical authentication

All 20 herbs were authenticated macroscopically and microscopically. Macroscopic examinations included measurements of appearance, size, shape, color, texture, odor, taste, fracture and other characteristics of a herb according to pharmacopoeias [10-13]. Microscopic examinations determined characteristic elements of each herb in both tissue and powder forms. In cross sectional examination, herbal material was softened by immersion in water, alcohol or glycerin prior to sectioning. Sliced tissue, prepared with a microtome, was mounted on a glass microscope slide and clarified with chloral hydrate, lactochloral and/or sodium hypochlorite, followed by phloroglucinol, potassium iodide or Sudan Red. In powder analysis, each herbal material was pulverized to 65-mesh in size, mounted on a microscope slide, cleared with chloral hydrate, lactochloral and/or sodium hypochlorite, and then examined for the presence, size, shape and numbers of characteristic elements and inclusions such as vessels, calcium crystals, crystalline fibers, stone cells and starch grains. The examination protocols followed the World Health Organization (WHO) Quality Control Methods for Medicinal Plant Materials [14], the Pharmacopoeia of the People's Republic of China (CP) [10] and the Hong Kong Chinese Materia Medica Standards (HKCMMS) [11-13]. The recorded macroscopic and microscopic data for each herb were verified against those in the CP and/or the HKCMMS, coupled with visual comparison with available reference samples.

Reference marker compounds and reagents

Reference marker compounds for qualitative and quantitative high performance liquid chromatography (HPLC) were obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and further validated by mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) and purity (>98%) analysis with HPLC and/or liquid chromatography-mass spectrometry (LC-MS). Chemicals and general solvents were of reagent grade and HPLC solvents were of HPLC grade (BDH, United Kingdom).

Purity and contaminant determination

Purity rubric tests, including foreign matters, total ash, acid-insoluble ash, water and extractive contents, were carried out according to the CP or HKCMMS [10-13]. Determination of heavy metals (arsenic, cadmium, mercury, and lead), pesticides, microbials and microbial toxin (aflatoxin) was carried out according to the HKCMMS [11-13]. Briefly, for heavy metal analysis, the herbal matrix was dissolved by microwave-assisted acid digestion, and the presence and quantity of mercury, lead, arsenic, and/or cadmium, if any, were determined by inductively coupled plasma-mass spectrometry (ICP-MS). Pesticide residues (e.g., aldrin, dieldrin, chlordane, dichlorodiphenyltrichloroethane, endrin, heptachlor, hexachlorobenzene, hexachlorocyclohexane isomers, lindane and quintozene) were quantitatively determined with gas chromatography (GS). Mycotoxins (aflatoxins B1, B2, G1 and G2) were detected as previously described [11-13,15]. Microorganism examinations included total bacteria, mould and yeast, Escherichia coli and Salmonella counts as described in the CP [10].

Chemical standardization

Chromatographic fingerprint analysis HPLC fingerprinting with one or more reference markers was carried out according to the HKCMMS and/or CP [10-13]. As an example, the procedure used for Rhizoma Coptidis (Huanglian) is described here. The herb was ground to powder, extracted in MeOH by ultrasonication for 30 minutes and filtered. The chromatographic system consisted of an Agilent 1100 HPLC system (Agilent Technologies, USA) equipped with a secondary pump, a diode-array detector, an autosampler, and a column compartment, an Alltech Alltima C18 column (4.6 × 250 mm) (Alltech, USA) packed with 5 μm diameter particles and an Alltech Alltima guard column (7.5 × 4.6 mm, 5 μm) (Alltech, USA); solvent system: 0.1% trifluoroacetic acid (%, v/v) (A) and acetonitrile (%, v/v) (B) with a linear gradient elution, 0% B-50% B at 0-48 minutes, 50% B-100% B at 48-55 minutes, 100% B was held for five minutes; flow rate: 1.0 ml/min; detection: 346 nm; reference marker: berberine. Information of the reference marker compounds for each herb is available in Additional File 1.

Quantitative analysis

Quantitative determination of selected marker compound(s) in each herb was performed with HPLC analysis. As an example, the quantitative analysis of Cortex Magnoliae Officinalis (Houpo) is described here. Preparation of the herb and the HPLC setup were the same as described above. The mobile phase contained 0.4% formic acid and acetonitrile (35:65); flow rate: 1 ml/min; detection: 294 nm. Information of the reference marker compounds for each herb is available in Additional File 1.

Inter-laboratory methods validation

Inter-laboratory validation of fingerprint and quantitative HPLC analytical protocols were carried out in laboratories at the Chinese University of Hong Kong and the University of Western Sydney prior to use. Both laboratories followed the identical experimental protocols and the results were critically compared.

Production of herbal extracts and the IBS-20 formula

The 20 dried herbs were individually reduced in size by milling or slicing and mixed in the prescribed proportion (% w/w), followed by extraction with water under GMP at the Hong Kong Institute of Biotechnology (Hong Kong Special Administrative Region, China). Briefly, the herb mixture (400 kg) was decocted with 10-fold (w/v) of boiling distilled water for 60 minutes, cooled and collected. After fresh boiling water was added, the mixture was decocted for a second time. The cooled extracts were pooled, filtered, concentrated and spray dried to obtain a powder (34% yield w/w based on raw herbs). An aliquot was set aside for chemical and pre-clinical biological studies. The remaining powdered extract was then formulated with water-soluble starch (excipient) in a ratio of 1:1 into the clinical product in the form of an aluminum foil packed sachet.

Chemical standardization of the IBS-20 formula

Chemical standardization of the clinical herbal extract with selected reference markers was performed with HPLC coupled with diode array detection and atmospheric pressure chemical ionization mass spectrometry (HPLC-DAD-APCIMS) analysis. Briefly, the powdered extract was sonicated in MeOH for 30 minutes and filtered through a cellulose syringe filter. An aliquot (10 μl) of filtrate was injected into an Agilent 1100 HPLC system equipped with an Alltech Alltima C18 column (4.6 × 250 mm, 5 μm diameter). The mobile phase consisted of 0.1% trifluoroacetic acid in water (v/v) (A) and acetonitrile (B) with the gradient elution conditions as follows: 12% B-13% B at 0-10 minutes, 13% B - 16% B at 10-40 minutes, 16% B-36.4% B at 40-67 minutes, 36.4% B-60% B at 67-100 minutes, from 100-120 minutes a gradient was applied to 100% B and was held for five minutes, followed by a 10-minute equilibration period at 12% B; flow rate: 1.5 ml/min; temperature: 27.5°C (constant). For detection, an Agilent 1100 series LC/MSD trap (Agilent Technologies, USA) was connected to the HPLC system via an APCIMS interface. Ultra-high purity helium was used as the collision gas and high purity nitrogen as the nebulizing gas. The optimized parameters in the positive ionization mode were as follows: nebulizer gas pressure: 50 psi; dry gas flow: 5.0 l/min; dry temperature: 350°C; vaporizer temperature: 400°C; full-scan MS analysis in the range of m/z 100-2200. The reference marker compounds present in the sample were identified by retention time, MS fragmentation and UV spectra.

Stability monitoring

The stability of the chemically standardized herbal formula was monitored in real time over a period of at least one year. The HPLC fingerprint profiles as well as the quantitative content of eight selected major marker compounds in the clinical formula were measured on days 0, 2, 3, 7, 14, 30, 60, 90, 180, 360, 450 post-production with HPLC and LC-MS respectively.

Results and discussion

During the selection of herbs, we paid special attention to the cases where the Chinese names correspond to more than one species. For example, Cortex Phellodendri refers to the bark of either Phellodendron amurense or Phellodendron chinense which are similar in macroscopic appearance and used interchangeably in Chinese medicine. Our studies in support of the HKCMMS [11] revealed significant differences in microscopic and chemical profiles of the two species using thin-layer chromatographic (TLC) and HPLC fingerprints as well as differences in contents using quantitative HPLC analysis. Microscopically, the cortex of Phellodendron chinense is broader than that of Phellodendron amurense (Figure 1), while the stone cells are more abundant and scattered in the outer layer of phloem of the former species (Figure 1a) but are sparsely scattered in the cortex of the latter (Figure 1b). Chemically, the marker compound profiles also differ significantly (Figure 2). In Phellodendron chinense (Figure 2a), berberine predominates while palmatine is not discernible. On the other hand, both berberine and palmatine are present and appear to be similar in concentration in the cortex of Phellodendron amurense (Figure 2b). Thus, to ensure chemically and biologically reproducible batches, we decided to use the cortex of Phellodendron amurense in our preparation.
Figure 1

Microscopic features of cross section. (a) Phellodendron chinensis bark. (b). Phellodendron amurense bark 1: Cork; 2: Cortex; 3: Stone cells; 4: Prisms of calcium oxalate; 5: Phloem; 6: Phloem fibres and crystal fibres; 7: Phloem rays.

Figure 2

HPLC chromatograms. (a). Phellodendron chinensis bark. (b) Phellodendron amurense bark 1: palmatine; 2: berberine.

Microscopic features of cross section. (a) Phellodendron chinensis bark. (b). Phellodendron amurense bark 1: Cork; 2: Cortex; 3: Stone cells; 4: Prisms of calcium oxalate; 5: Phloem; 6: Phloem fibres and crystal fibres; 7: Phloem rays. HPLC chromatograms. (a). Phellodendron chinensis bark. (b) Phellodendron amurense bark 1: palmatine; 2: berberine. Purity rubric tests indicated that the herbs met the limits established by the CP and/or HKCMMS [10-13] (in the cases where regulatory standards are available) (Table 1). Tests for contaminants showed that none of the 20 herbs exceeded the standards established by the CP and/or HKCMMS [10-13] (Table 2).
Table 1

Regulatory standards and experimental results of purity and contaminant tests

AshExtractives


Pharmaceutical nameForeign mattersTotal ashAcid-insoluble AshWater contentWater-soluble extractivesEthanol-soluble extractives
Radix Angelicae Dahuricae--(<1.0%)6.0%a(4.1%)1.5%a(<1.0%)14%a(10%)--(27%)15%a(17%)
Herba Artemisiae Scopariae--(<1.0%)4.0%a(2.9%)2.0%a(<1.0%)15%a(9.7%)--(25%)--(17%)
Rhizoma Atractylodis Macrocephalae--(<1.0%)5.0%a(3.7%)1.0%a<1.0%)--(10%)--(67%)--(12%)
Radix Aucklandiae2.0%b(<1.0%)4.5%b(3.2%)1.0%b(<1.0%)14%b(10%)65%b(68%)15%b(27%)
Radix Bupleuri2.0%b(<1.0%)7.7%b(1.0%)3.5%b(2.8%)5.0%b(4.4%)12%b(22%)11%b(17%)
Pericarpium Citri Reticulatae--(<1.0%)--(4.7%)--(1.4%)13%a(11%)--(39%)--(39%)
Radix Codonopsis1.0%b(<1.0%)6.0%b(4.1%)2.5%b(<1.0%)12%b(10%)41%b(60%)21%b(52%)
Semen Coicis2.0%a(<1.0%)3.0%a(2.3%)--(<1.0%)15%a(9.9%)--(6.0%)5.5%a(6.0%)
Rhizoma Coptidis2.0%b(<1.0%)5.0%b(2.5%)2.5%b(<1.0%)12%b(7.5%)17%b(23%)14%b(19%)
Cortex Fraxini--(<1.0%)8.0%a(4.7%)--(1.5%)7.0%a(6.5%)--(8.0%)8.0%a(8.7%)
Radix et Rhizoma Glycyrrhizae Praeparata cum Melle--(<1.0%)5.0%a(3.1%)1.0%a(<1.0%)10%a(8.1%)--(47%)--(43%)
Cortex Magnoliae Officinalis1.0%b(<1.0%)8.0%b(4.50%)3.5%b(1.6%)12%b(8.3%)3.0%b(8.0%)5.0%b(9.0%)
Radix Paeoniae Alba1.0%b(<1.0%)4.0%b(2.1%)1.0%b(<1.0%)14%b(7.1%)21%b(22%)16%b(17%)
Semen Plantaginis--(<1.0%)6.0%a(3.2%)2.0%a(<1.0%)12%a(10%)--(12%)--(3.3%)
Cortex Phellodendri Amurensis1.0%b(<1.0%)8.5%b(7.3%)1.0%b(<1.0%)11%b(8.7%)9.0%b(17%)12%b(16%)
Herba Pogostemonis2.0%a(<1.0%)11%a(8.6%)4.0%a(2.3%)14%a(9.1%)--(14%)2.5%a(10%)
Poria--(<1.0%)4.0%a(2.4%)2.0%a(<1.0%)15%a(9.5%)--(2.0%)--(2.6%)
Radix Saposhnikoviae2.0%b(<1.0%)7.0%b(5.1%)2.5%b(1.8%)13%b(7.7%)22%b(27%)19%b(25%)
Fructus Schisandrae Chinensis1.0%a(<1.0%)--(4.5%)--(1.4%)--(12%)--(30%)--(31%)
Rhizoma Zingiberis Praeparatum--(<1.0%)7.0%a(4.6%)--(<1.0%)--(5.8%)--(13%)--(7.8%)

Note: Data in parentheses are experimental results of the samples.

a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition)

b Limit required by the Hong Kong Chinese Materia Medica Standards

Table 2

Limits and experimental results of toxic contaminant tests

TestLimit (maximum)Herbal formula
Heavy metals:
Arsenic (As)2.0 mg/kgb0.30 mg/kg
Cadmium (Cd)0.3 mg/kgb0.13 mg/kg
Mercury (Hg)0.2 mg/kgbNot detectable
Lead (Pb)5.0 mg/kgb0.34 mg/kg
Pesticide residues:
Aldrin and dieldrin (sum of)0.05 mg/kgbNot detectable
Chlordane (sum of cis-, trans- and oxychlordane)0.05 mg/kgbNot detectable
DDT (sum of p,p'-DDT, o,p'-DDT, p,p'-DDE and p,p'-TDE)1.0 mg/kgbNot detectable
Endrin0.05 mg/kgbNot detectable
Heptachlor (sum of heptachlor and heptachlor epoxide)0.05 mg/kgbNot detectable
Hexachlorobenzene0.1 mg/kgbNot detectable
Hexachlorocyclohexane isomers (α-, β- and δ- hexachlorocyclohexane)0.3 mg/kgbNot detectable
Lindane (γ-hexachlorocyclohexane)0.6 mg/kgbNot detectable
Quintozene (sum of quintozene, pentachloroaniline and methyl pentachlorophenyl sulphide)1.0 mg/kgbNot detectable
Mycotoxins:
Aflatoxin B15 μg/kgbNot detectable
Sum of aflatoxins B1, B2, G1 and G210 μg/kgbNot detectable
Microbiological:
Total plate counts1000 colony/ga< 10 colony/g
Yeast and mould100 colony/ga< 10 colony/g
Escherichia coliAbsentaAbsent
Salmonella speciesAbsentAbsent

a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition)

b Limit required by the Hong Kong Chinese Materia Medica Standards

Regulatory standards and experimental results of purity and contaminant tests Note: Data in parentheses are experimental results of the samples. a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition) b Limit required by the Hong Kong Chinese Materia Medica Standards Limits and experimental results of toxic contaminant tests a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition) b Limit required by the Hong Kong Chinese Materia Medica Standards Each herb possesses a unique chemical profile of secondary metabolites which may be used as marker compounds for identification and standardization purposes. Some of these marker compounds have been related to the therapeutic efficacy of the herbs, as exemplified by our recent discovery of magnolol and honokiol as the active antispasmodic effects of Cortex Magnolia Officinalis [16]. Therefore, the marker content, especially that of biologically active compounds, may be used to confirm both the identity and quality of a herb. Additional File 1 summarizes the status of the qualitative (fingerprinting) and quantitative (HPLC) analyses of the herbs. Figure 3 shows the HPLC fingerprint of Rhizoma Coptidis as an example, whereas Table 3 provides the quantitative results of individual herbs. For those herbs that have CP and/or HKCMMS limits for the markers, the marker contents were found to be above the limits in all cases.
Figure 3

Chromatographic fingerprint of Rhizoma Coptidis extract. Number shows in the bracket(s) represent the relative retention of the peak to the marker peak: 1 (0.81); 2 (0.88); 3 (0.89, jatrorrhizine); 4 (0.90); 5 (0.93, coptisine); 6 (0.98, palmatine); 7 (marker, berberine).

Table 3

Quantitative assay results of the component herbs

Pharmaceutical nameReference markerLimit(minimum)Analytical results
Radix Angelicae DahuricaeImperatorin0.080%a0.081%
Herba Artemisiae ScopariaeChlorogenic acid--0.31%
Rhizoma Atractylodis Macrocephalae------
Radix AucklandiaeSum of costunolide and dehydrocostus lactone2.2%b2.7%
Radix BupleuriSaikosaponin a0.16%b0.43%
Pericarpium Citri ReticulataeHesperidin3.5%a6.5%
Radix CodonopsisLobetyolin0.029%b0.069%
Semen CoicisGlycerol trioleate0.50a1.1%
Rhizoma CoptidisBerberinePalmatine4.1%b0.30%b7.4%1.8%
Cortex FraxiniSum of aesculetin and esculin1.0%a2.1%
Radix et Rhizoma Glycyrrhizae Praeparata cum MelleGlycyrrhizic acid--2.7%
Cortex Magnoliae OfficinalisSum of magnolol and honokiol2.0%b2.3%
Radix Paeoniae AlbaPaeoniflorin1.6%a1.8%
Semen Plantaginis------
Cortex Phellodendri AmurensisBerberinePalmatine0.33%b0.18%b0.95%0.40
Herba PogostemonisPatchouli alcohol0.10%a0.23%
Poria------
Radix SaposhnikoviaeSum of prim-O-Glucosylcimifugin and 5-O-methylvisammioside0.24%b0.42%
Fructus Schisandrae ChinensisSchisandrin0.40%a0.66%
Rhizoma Zingiberis Praeparatum6-Gingerol--0.31%

a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition).

b Limit required by the Hong Kong Chinese Materia Medica Standards.

Quantitative assay results of the component herbs a Limit required by the Pharmacopoeia of the People's Republic of China (2005 edition). b Limit required by the Hong Kong Chinese Materia Medica Standards. Chromatographic fingerprint of Rhizoma Coptidis extract. Number shows in the bracket(s) represent the relative retention of the peak to the marker peak: 1 (0.81); 2 (0.88); 3 (0.89, jatrorrhizine); 4 (0.90); 5 (0.93, coptisine); 6 (0.98, palmatine); 7 (marker, berberine). Inter-laboratory validation of fingerprint and quantitative HPLC demonstrated that the absolute deviation from mean (ADM) values of honokiol and magnolol in Cortex Magnoliae Officinalis were 0.43 and 1.11% respectively, confirming method reproducibility of the present study (Table 4). Similar results were obtained for all other herbs and no significant discrepancies were noted among the findings in Hong Kong and Australian laboratories.
Table 4

Inter-laboratory validation of quantitative assay of Cortex Magnoliae Officinalis

Percentage content (%)ADM (%)
CUHK resultUWS result
Honokiol0.83550.84270.43
Magnolol1.48151.51481.11

Note: ADM (absolute deviation from mean) = (| D1 - mean|/mean) × 100%, where mean = (D1+D2)/2; D1 = the first value, D2 = the second value

CUHK: Chinese University of Hong Kong

UWS: University of Western Sydney

Inter-laboratory validation of quantitative assay of Cortex Magnoliae Officinalis Note: ADM (absolute deviation from mean) = (| D1 - mean|/mean) × 100%, where mean = (D1+D2)/2; D1 = the first value, D2 = the second value CUHK: Chinese University of Hong Kong UWS: University of Western Sydney The chemical standardization of the IBS-20 formula employed a HPLC-DAD-APCIMS system (Figure 4). Mass spectral analysis revealed 20 marker compounds attributable to ten herbs, of which eight markers were sufficient for quantitative estimation (Table 5). The fact that not all markers of the 20 herbs were detected was most likely due to low solubility of the lipophilic markers in the aqueous decoction. For the three herbs that have no established markers, namely, Rhizoma Atractylodis Macrocephalae, Semen Plantaginis, and Poria, no attempt was made to identify any ingredient from them.
Figure 4

Chromatographic fingerprint of the IBS-20 formula.

Table 5

Identification of markers in the HPLC fingerprint of the formula by LC-MS analysis

APCI MS Data (Positive Ion)

PeakIdentificationTime (min)M/QMIPaOther PeaksMS2 of M/QMIPPlant SourcebContent in formulation(mg/kg)
1Esculin6.4341 (M+H)+179179FR
2Chlorogenic acid10.3355 (M+H)+163163AS
3Aesculetin12.0179 (M+H)+134, 123, 109FR310
4Paeoniflorin18.8498 (M+H2O)+301, 179301, 179PL
5prim-O-Glucosylcimifugin23.8469 (M+H)+307SD
6Magnoflorine32.2342 (M)+297, 265CC, PA
7Liquiritin35.9419 (M+H)+307, 257GU
85-O-Methylvisamminoside49.9453 (M+H)+291290SD
9Hesperidin52.0610 (M)+465, 449, 303463CR1460
10Columbamine60.2338 (M)+323, 294CC
11Jatrorrhizine61.3338 (M)+323, 294CC
12Epiberberine61.3336 (M)+CC
13Coptisine61.4320 (M)+304, 292CC
14Palmatine66.5352 (M)+337, 308CC, PA420
15Berberine67.3336 (M)+321, 292CC, PA1620
16Glycyrrhizic acid76.2823 (M+H)+647, 471, 453, 406GU780
17Schisandrin81.8433 (M+H)+415SC140
18Honokiol93.3266 (M)+263MO63
19Magnolol98.6266 (M)+261MO93
20Schisandrin A107.7417 (M+H)+402, 347, 316SC

Note: Peak number refers to the chromatographic fingerprint of the clinical preparation (Figure 4). Peaks 6, 10, 12, and13 were identified by LC-MS/MS2 analysis based on the literature values [17,18] and other peaks were identified by comparison of authentic chemicals. Jatrorrhizine and epiberberine (peaks 11, 12) were co-eluted with the same retention times.

a Molecular or quasi-molecular ion peak; b FR: Fraxinus rhynchophylla; AS: Artemisia scoparia; PL: Paeonia lactiflora; SD: Saposhinikovia divaricata; GU: Glycyrrhiza uralensis; CR: Citrus reticulata; CC: Coptis chinensis; PA: Phellodendron amurense; SC: Schisandra chinensis; MO: Magnolia officinalis.

Chromatographic fingerprint of the IBS-20 formula. Identification of markers in the HPLC fingerprint of the formula by LC-MS analysis Note: Peak number refers to the chromatographic fingerprint of the clinical preparation (Figure 4). Peaks 6, 10, 12, and13 were identified by LC-MS/MS2 analysis based on the literature values [17,18] and other peaks were identified by comparison of authentic chemicals. Jatrorrhizine and epiberberine (peaks 11, 12) were co-eluted with the same retention times. a Molecular or quasi-molecular ion peak; b FR: Fraxinus rhynchophylla; AS: Artemisia scoparia; PL: Paeonia lactiflora; SD: Saposhinikovia divaricata; GU: Glycyrrhiza uralensis; CR: Citrus reticulata; CC: Coptis chinensis; PA: Phellodendron amurense; SC: Schisandra chinensis; MO: Magnolia officinalis. The stability results showed that the concentrations of these compounds did not change significantly from the date of production (day 0) to the last day of analysis, confirming the chemical stability of the IBS-20 formula under the storage conditions (Figure 5).
Figure 5

Stability of the IBS-20 formula. The ratio was calculated by the content of the marker at the date of measurement to that at the starting date.

Stability of the IBS-20 formula. The ratio was calculated by the content of the marker at the date of measurement to that at the starting date.

Conclusion

A QA/QC program involving good supply practice acquisition, botanical validation, chemical profiling of the component herbs, as well as the establishment of a chemical standardization protocol and stability monitoring has been implemented on a 20-herb botanical preparation, the IBS-20 formula. The results of this study demonstrate that it is possible to establish a QA/QC program to monitor the quality of poly-herbal formulations employing botanical and chemical methods. In particular, the generation of a fingerprint HPLC chromatographic protocol in which the identities of a series of appropriate marker compounds, including relevant biologically active constituents, were identified for use in product standardization, coupled with a stability study procedure involving the LC-MS quantitation of major chemical markers, represent major advances in the development of quality control methods for poly-herbal Chinese medicine products for clinical studies and therapy.

Abbreviations

ADM: absolute deviation from mean; APCIMS: atmospheric pressure chemical ionization mass spectrometry; CP: Pharmacopoeia of the People's Republic of China; DAD: diode array detection; GMP: good manufacturing practice; HKCMMS: Hong Kong Chinese Materia Medica Standard; HPLC: high-performance liquid chromatography; IBS: irritable bowel syndrome; ICP-MS: inductively coupled plasma-mass spectrometry; GS: gas chromatography; LC-MS: liquid chromatography-mass spectrometry; NMR: nuclear magnetic resonance; QA: quality assurance; QC: quality control; TLC: thin-layer chromatographic; UV: ultra violet; WHO: World Health Organization.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SPI coordinated the research and drafted the manuscript. MZ, YFX, MLC, YYZ, YWT and SHT performed the experiments. JJYS, AB, BB, HHSF and CTC supervised this project and revised the manuscript. All authors read and approved the final version of the manuscript.

Additional file 1

Summary of the herbs and their chemical marker. Click here for file
  8 in total

1.  Review of randomised controlled trials of traditional Chinese medicine.

Authors:  J L Tang; S Y Zhan; E Ernst
Journal:  BMJ       Date:  1999-07-17

Review 2.  Methodological aspects of Traditional Chinese Medicine (TCM).

Authors:  Edzard Ernst
Journal:  Ann Acad Med Singapore       Date:  2006-11       Impact factor: 2.473

3.  High performance liquid chromatography-mass spectrometry analysis of protoberberine alkaloids in medicine herbs.

Authors:  Lingling Ren; Xingya Xue; Feifang Zhang; Qing Xu; Xinmiao Liang
Journal:  J Sep Sci       Date:  2007-04       Impact factor: 3.645

Review 4.  Complementary and alternative medicine for IBS in adults: mind-body interventions.

Authors:  David J Kearney; Janelle Brown-Chang
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-09-30

Review 5.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

6.  Determination of aflatoxins in Chinese medicinal herbs by high-performance liquid chromatography using immunoaffinity column cleanup Improvement of recovery.

Authors:  Siu-Po Ip; Chun-Tao Che
Journal:  J Chromatogr A       Date:  2006-11-02       Impact factor: 4.759

7.  Structural analyses of protoberberine alkaloids in medicine herbs by using ESI-FT-ICR-MS and HPLC-ESI-MS(n).

Authors:  Wei Wu; Fengrui Song; Cunyu Yan; Zhiqiang Liu; Shuying Liu
Journal:  J Pharm Biomed Anal       Date:  2004-12-22       Impact factor: 3.935

8.  Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum.

Authors:  Sunny Sun-Kin Chan; Ming Zhao; Lixing Lao; Harry H Fong; Chun-Tao Che
Journal:  Planta Med       Date:  2008-03       Impact factor: 3.352

  8 in total
  7 in total

1.  Anti-Inflammatory Activities of a Chinese Herbal Formula IBS-20 In Vitro and In Vivo.

Authors:  Zhonghan Yang; Viktoriya Grinchuk; Siu Po Ip; Chun-Tao Che; Harry H S Fong; Lixing Lao; Justin C Wu; Joseph J Sung; Brian Berman; Terez Shea-Donohue; Aiping Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-22       Impact factor: 2.629

Review 2.  Discovery and Current Status of Evaluation System of Bioavailability and Related Pharmaceutical Technologies for Traditional Chinese Medicines--Flos Lonicerae Japonicae--Fructus Forsythiae Herb Couples as an Example.

Authors:  Wei Zhou; Baochang Cai; Jinjun Shan; Shouchuan Wang; Liuqing Di
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

Review 3.  Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications.

Authors:  Ramesh C Gupta; Dennis Chang; Srinivas Nammi; Alan Bensoussan; Kellie Bilinski; Basil D Roufogalis
Journal:  Diabetol Metab Syndr       Date:  2017-07-26       Impact factor: 3.320

Review 4.  Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals.

Authors:  Neha Arora Chugh; Shreya Bali; Ashwani Koul
Journal:  Integr Med Res       Date:  2018-03-28

5.  Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century.

Authors:  Raman Chawla; Pallavi Thakur; Ayush Chowdhry; Sarita Jaiswal; Anamika Sharma; Rajeev Goel; Jyoti Sharma; Smruti Sagar Priyadarshi; Vinod Kumar; Rakesh Kumar Sharma; Rajesh Arora
Journal:  J Diabetes Metab Disord       Date:  2013-07-04

6.  Anti-inflammatory activities of Ganoderma lucidum (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus.

Authors:  Zhe Cai; Chun Kwok Wong; Jie Dong; Delong Jiao; Man Chu; Ping Chung Leung; Clara Bik San Lau; Ching Po Lau; Lai Shan Tam; Christopher Wai Kei Lam
Journal:  Chin Med       Date:  2016-04-29       Impact factor: 5.455

Review 7.  Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives.

Authors:  Chun-Tao Che; Zhi Jun Wang; Moses Sing Sum Chow; Christopher Wai Kei Lam
Journal:  Molecules       Date:  2013-05-03       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.